Resverlogix Corp. (TSE:RVX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Resverlogix Corp. has announced a strategic financial maneuver by extending their US$6.0 million debenture with Hepalink for an additional two years, now maturing on May 13, 2026, while also removing Hepalink’s conversion rights and increasing the interest rate from 12% to 18%. The company, a leader in epigenetic therapies, is working towards advancing treatments for cardiovascular disease and other chronic conditions. The amendment awaits formal documentation and approvals, including the nod from the Toronto Stock Exchange.
For further insights into TSE:RVX stock, check out TipRanks’ Stock Analysis page.
